Published in Eur J Biochem on July 01, 2004
Cross genome comparisons of serine proteases in Arabidopsis and rice. BMC Genomics (2006) 1.48
Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem Cell Biol (2008) 1.07
Oral enzyme therapy for celiac sprue. Methods Enzymol (2012) 1.03
Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J Histochem Cytochem (2009) 0.99
Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther (2008) 0.99
Life cycle stage-resolved proteomic analysis of the excretome/secretome from Strongyloides ratti--identification of stage-specific proteases. Mol Cell Proteomics (2011) 0.94
Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors. J Histochem Cytochem (2012) 0.89
Targeted modification of wheat grain protein to reduce the content of celiac causing epitopes. Funct Integr Genomics (2012) 0.88
Structural analysis of prolyl oligopeptidases using molecular docking and dynamics: insights into conformational changes and ligand binding. PLoS One (2011) 0.87
Hypothalamic prolyl endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in mice. Proc Natl Acad Sci U S A (2014) 0.85
Crystal structure of Leishmania major oligopeptidase B gives insight into the enzymatic properties of a trypanosomatid virulence factor. J Biol Chem (2010) 0.83
OsPOP5, a prolyl oligopeptidase family gene from rice confers abiotic stress tolerance in Escherichia coli. Int J Mol Sci (2013) 0.82
Oligopeptidase B from L. amazonensis: molecular cloning, gene expression analysis and molecular model. Parasitol Res (2007) 0.82
Oligopeptidase B from Leishmania amazonensis: molecular cloning, gene expression analysis and molecular model. Parasitol Res (2007) 0.81
Prolyl endopeptidase-deficient mice have reduced synaptic spine density in the CA1 region of the hippocampus, impaired LTP, and spatial learning and memory. Cereb Cortex (2012) 0.81
Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site. Biochem J (2004) 0.75
Distribution, classification, domain architectures and evolution of prolyl oligopeptidases in prokaryotic lineages. BMC Genomics (2014) 0.75
Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci (2007) 1.75
Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A (2005) 1.67
Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology (2007) 1.64
Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev (2012) 1.62
Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp Neurol (2010) 1.59
Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci (2002) 1.51
Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther (2002) 1.19
Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J Neurochem (2010) 1.17
Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis (2005) 1.15
Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm (2010) 1.11
Catechol-O-methyltransferase gene polymorphism and chronic human pain: a systematic review and meta-analysis. Pharmacogenet Genomics (2012) 1.08
Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem Cell Biol (2008) 1.07
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. J Med Chem (2006) 1.06
Resistance to salt-induced hypertension in catechol-O-methyltransferase-gene-disrupted mice. J Hypertens (2003) 1.01
Distribution of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble COMT deficient mice. J Neurochem (2010) 0.99
Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J Histochem Cytochem (2009) 0.99
Transcriptional profiling of C57 and DBA strains of mice in the absence and presence of morphine. BMC Genomics (2007) 0.95
D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berl) (2003) 0.92
Are genetic variants of COMT associated with addiction? Pharmacogenet Genomics (2010) 0.92
Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J Comp Neurol (2008) 0.92
Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors. J Med Chem (2007) 0.91
Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp Neurol (2009) 0.91
Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China. Am J Clin Nutr (2006) 0.91
Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease. Brain Behav (2013) 0.91
Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. Biochem Pharmacol (2002) 0.90
Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem (2005) 0.90
Catechol-O-methyltransferase and pain. Int Rev Neurobiol (2010) 0.90
The multiple faces of quercetin in neuroprotection. Expert Opin Drug Saf (2009) 0.89
Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors. J Histochem Cytochem (2012) 0.89
New prolyl oligopeptidase inhibitors developed from dicarboxylic acid bis(l-prolyl-pyrrolidine) amides. J Med Chem (2003) 0.87
Distribution of immunoreactive prolyl oligopeptidase in human and rat brain. Neurochem Res (2007) 0.87
Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure. J Med Chem (2006) 0.87
Characterization of membrane-bound prolyl endopeptidase from brain. FEBS J (2008) 0.87
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J Med Chem (2005) 0.86
Intracerebroventricular antisense knockdown of G alpha i2 results in ciliary stasis and ventricular dilatation in the rat. BMC Neurosci (2007) 0.86
Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase. Biochimie (2012) 0.86
Strong preferences of dopamine and l-dopa towards lipid head group: importance of lipid composition and implication for neurotransmitter metabolism. J Neurochem (2012) 0.85
Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats. Basic Clin Pharmacol Toxicol (2007) 0.85
Over-expression of a human chromosome 22q11.2 segment including TXNRD2, COMT and ARVCF developmentally affects incentive learning and working memory in mice. Hum Mol Genet (2009) 0.84
Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures. Brain Res (2008) 0.84
Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. Biochem Pharmacol (2006) 0.84
Different viabilities and toxicity types after 6-OHDA and Ara-C exposure evaluated by four assays in five cell lines. Toxicol In Vitro (2007) 0.84
Sequential expression, activity and nuclear localization of prolyl oligopeptidase protein in the developing rat brain. Dev Neurosci (2010) 0.83
Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther (2003) 0.83
ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm (2010) 0.83
The use of low-molecular-weight PEIs as gene carriers in the monkey fibroblastoma and rabbit smooth muscle cell cultures. J Gene Med (2002) 0.83
The role of PEI structure and size in the PEI/liposome-mediated synergism of gene transfection. Plasmid (2008) 0.83
Four day inhibition of prolyl oligopeptidase causes significant changes in the peptidome of rat brain, liver and kidney. Biochimie (2012) 0.82
Different synergistic roles of small polyethylenimine and Dosper in gene delivery. J Control Release (2003) 0.82
Effect of genetic modifications in the synaptic dopamine clearance systems on addiction-like behaviour in mice. Basic Clin Pharmacol Toxicol (2010) 0.82
High correlation between in vivo [123I]β-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats. EJNMMI Res (2013) 0.81
Agonists for neuropeptide Y receptors Y1 and Y5 stimulate different phases of feeding in guinea pigs. Br J Pharmacol (2003) 0.81
ApoE3 mediated polymeric nanoparticles containing curcumin: apoptosis induced in vitro anticancer activity against neuroblastoma cells. Int J Pharm (2012) 0.81
Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology (2011) 0.81
Tissue histopathology, clinical chemistry and behaviour of adult Comt-gene-disrupted mice. J Appl Toxicol (2003) 0.81
Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals. Neurobiol Aging (2009) 0.80
Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease. Scand J Gastroenterol (2007) 0.80
Hunting for peptide substrates of prolyl oligopeptidase: classical versus non-classical bioactive peptides. CNS Neurol Disord Drug Targets (2011) 0.80
Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. Phytomedicine (2010) 0.80
Ara-C induces apoptosis in monkey fibroblast cells. Toxicol In Vitro (2003) 0.80
Increase in free choice oral ethanol self-administration in catechol-o-methyltransferase gene-disrupted male mice. Basic Clin Pharmacol Toxicol (2008) 0.80
Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. J Clin Immunol (2012) 0.80
Synergism in gene delivery by small PEIs and three different nonviral vectors. Int J Pharm (2004) 0.80
Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. Toxicology (2008) 0.80
Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans. Eur J Med Chem (2011) 0.79
Interactions of inhibitor molecules with the human CYP2E1 enzyme active site. Eur J Pharm Sci (2012) 0.79
Effect of cell-surface glycosaminoglycans on cationic carrier combined with low-MW PEI-mediated gene transfection. Int J Pharm (2004) 0.79
Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig. Br J Pharmacol (2002) 0.79
A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J Med Chem (2004) 0.79
Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice. Psychopharmacology (Berl) (2010) 0.78
Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors. Int Rev Neurobiol (2010) 0.78
Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.78
Effect of forced chronic oral nicotine exposure on intravenous self-administration and rewarding properties of acute nicotine. Eur J Pharmacol (2008) 0.78
4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors. Bioorg Med Chem (2002) 0.78
Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum. Eur J Pharmacol (2003) 0.78
Sex-dependent compensated oxidative stress in the mouse liver upon deletion of catechol O-methyltransferase. Biochem Pharmacol (2009) 0.78
Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: a retrograde neurotracing study in the rat brain. Neurosci Lett (2008) 0.78
Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions. Basic Clin Pharmacol Toxicol (2007) 0.78
Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome. Biochem Pharmacol (2013) 0.78
Minocycline protects SH-SY5Y cells from 6-hydroxydopamine by inhibiting both caspase-dependent and -independent programmed cell death. J Neurosci Res (2011) 0.78
Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the picture? Int Rev Neurobiol (2010) 0.78
Advanced brain dopamine transporter imaging in mice using small-animal SPECT/CT. EJNMMI Res (2012) 0.78
A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine. Toxicol In Vitro (2006) 0.78
Dicarboxylic acid bis(L-prolyl-pyrrolidine) amides as prolyl oligopeptidase inhibitors. J Med Chem (2002) 0.77
Stress-induced analgesia and morphine responses are changed in catechol-O-methyltransferase-deficient male mice. Basic Clin Pharmacol Toxicol (2008) 0.77
Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells. Brain Res (2005) 0.77
Identification of novel CYP2A6 inhibitors by virtual screening. Bioorg Med Chem (2011) 0.77
Brain histamine and histamine H3 receptors following repeated L-histidine administration in rats. Life Sci (2003) 0.77
D-Isomer of gly-tyr-pro-cys-pro-his-pro peptide: a novel and sensitive in vitro trapping agent to detect reactive metabolites by electrospray mass spectrometry. Toxicol In Vitro (2010) 0.76
Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats. Eur J Pain (2011) 0.76
Metabolism of bilirubin by human cytochrome P450 2A6. Toxicol Appl Pharmacol (2012) 0.76
The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. Eur J Pharm Sci (2005) 0.76
Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats. Basic Clin Pharmacol Toxicol (2007) 0.76
Catechol-O-methyltransferase (COMT) protein expression and activity after dopaminergic and noradrenergic lesions of the rat brain. PLoS One (2013) 0.75
Reduced natriuretic response to acute sodium loading in COMT gene deleted mice. BMC Physiol (2002) 0.75
Different effects of scopolamine and inhibition of prolyl oligopeptidase on mnemonic and motility functions of young and 8- to 9-month-old rats in the radial-arm maze. Basic Clin Pharmacol Toxicol (2009) 0.75
Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site. Biochem J (2004) 0.75